Corey Davis

The Network’s Harm Reduction Legal Project works to address the legal and policy barriers that impede the establishment and expansion of evidence-based harm reduction measures such as naloxone distribution, syringe access programs, and access to evidence-based substance use disorder treatment. One of the questions frequently received by the Project is whether federal law prohibits harm reduction organizations and similar groups who are authorized to distribute naloxone from mailing the medication.

In this Q&A, Corey Davis, deputy director of the Network’s Southeastern Region Office and director of the Network’s Harm Reduction Legal Project; and Amy Lieberman, senior attorney, for the Network’s Harm Reduction Legal Project, discuss some of the key elements in the chapter they authored, Access to Care for Individuals with Opioid Use Disorder, for the Report.

This fact sheet briefly summarizes the state of the law in Idaho related to naloxone access, overdose Good Samaritan protections, and access to injection equipment.

This webinar focused on the legal and regulatory modifications during COVID-19, how they are being used to increase access treatment for opioid use disorder, and opportunities to permanently increase access to medications.

While states have passed various laws designed to increase access to naloxone, a life-saving opioid overdose reversal medication, none explicitly address the legality of dispensing naloxone that is past its expiration date. This fact sheet discusses whether Georgia laws forbid the prescription, dispensing, distribution, possession, or administration of expired naloxone and whether such actions impact the risk of civil liability for medical professionals who prescribe or dispense naloxone or laypeople who distribute or administer it.

This fact sheet discusses whether District of Columbia laws forbid the prescription, dispensing, distribution, possession, or administration of expired naloxone and whether such actions impact the risk of civil liability for medical professionals who prescribe or dispense naloxone or laypeople who distribute or administer it.

The Drug Enforcement Administration (DEA) has temporarily waived or clarified several regulations that may act as barriers to providing life-saving medications to those undergoing treatment for opioid use disorder during the COVID-19 Pandemic. These changes have the potential to dramatically increase access to these medication and the DEA should strongly consider extending many of these changes for the duration of the opioid public health emergency, which will remain even after the threat from COVID-19 subsides.

This fact sheet discusses whether Illinois laws forbids the prescription, dispensing, distribution, possession, or administration of expired naloxone.

The medications methadone and buprenorphine are extremely effective in reducing the harms associated with opioid use disorder. In light of the ongoing public health emergency associated with COVID-19 the federal government has recently taken a number of steps to increase access to these lifesaving medications.

This fact sheet discusses whether Illinois laws forbids the prescription, dispensing, distribution, possession, or administration of expired naloxone.

Overdose “Good Samaritan” laws are theoretically designed to encourage people to call for help in an overdose emergency by providing limited legal immunity to overdose victims and those who seek help for them, but many of these laws currently have limitations that discourage people from seeking help.

Opioid overdose is reversible through the timely administration of the medication naloxone and, where needed, the provision of other emergency care. In an attempt to reverse this epidemic of preventable overdose deaths, every state and the District of Columbia have modified their laws to increase access to naloxone, the standard first-line treatment for opioid overdose.